Chavarin Amarase

Chavarin Amarase

Auto-generated profile, based on publicly available information

Chavarin Amarase

Hip Fracture Research Unit, Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2025 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
NRNapol Ratanasermsub
Napol Ratanasermsub
CAChavarin Amarase
Chavarin Amarase
STSaran Tantavisut
Saran Tantavisut
PSPathit Sirichuchnin
Pathit Sirichuchnin
Background: Lesser trochanter displacement in intertrochanteric fractures has been linked to fracture instability and altered hip biomechanics, with evidence suggesting that proximal or medial displacement of the fragment by ≥ 10 mm may lead to poorer clinical outcomes. However, whether such displacement is associated with multidomain functional outcomes and patient performance remains unclear. Questions/purposes: In older adults with intertrochanteric fractures treated with internal fixation using a cephalomedullary nail, we asked: (1) Were functional outcome measures, including the Harris hip score (HHS), de Morton Mobility Index (DEMMI), and the Barthel Index, negatively associated with lesser trochanter displacement of ≥ 10 mm? (2) Was lesser trochanter displacement of ≥ 10 mm associated with a decreased ability to complete tasks during performance assessments and inferior performance scores on the Functional Reach Test (FRT), Timed Up and Go test (TUG), and 5 Times Sit-to-Stand (5TSTS) test? Methods: Between January 2021 and October 2023, four fellowship-trained orthopaedic surgeons at a Level I trauma center treated older adults with intertrochanteric hip fractures. Short cephalomedullary nails were used in approximately 90% of patients, typically for displaced fractures, including both stable and unstable types. Of the 123 patients treated with a cephalomedullary nail, 7% (9) were lost to follow-up before 1 year, 9% (11) died within 1 year, and 12% (15) were excluded based on predefined criteria, leaving 72% (88) of patients for analysis in this retrospective comparative study. There was no evidence of differential loss to follow-up or mortality between the displacement groups. Patients were divided into two groups based on postoperative lesser trochanter displacement: patients with < 10 mm of proximal or medial displacement, including an intact lesser trochanter (n = 44), and patients with displacement of ≥ 10 mm (n = 44). Baseline characteristics, including demographics, American Society of Anesthesiologists classification, and preinjury Barthel Index, did not differ between the groups. Functional outcomes, including the HHS, the DEMMI (which assesses mobility across a range of physical tasks), and the Barthel Index (which measures independence in activities of daily living) were assessed at 3 months and 1 year postoperatively. All three scores range from 0 to 100, with higher scores indicating better function. These capture different domains of recovery, allowing for a more comprehensive evaluation of patient outcomes. Performance tests (FRT, TUG, 5TSTS) were assessed at the same time points by experienced orthopaedic surgeons, and the groups were compared on those endpoints. The minimum clinically important difference (MCID) or minimal detectable change at 95% confidence (MDC95) values were: HHS (MCID = 16 to 18), DEMMI (MCID = 10), Barthel Index (MCID = 8.4), FRT (MDC95 = 6.4 to 8.2 cm), TUG (MCID = 2.9 to 4.9 seconds), and 5TSTS (MCID = 3.6 seconds). Results: We found no clinically important difference in HHS at either 3 months or 1 year. Patients whose fractures had < 10 mm of displacement showed higher DEMMI scores at 3 months (50 ± 15 versus 37 ± 13, mean difference 13 [95% confidence interval (CI) 7 to 19]; p < 0.001) and a borderline meaningful difference at 1 year (52 ± 17 versus 42 ± 15, mean difference 10 [95% CI 3 to 16]; p = 0.01). Barthel Index scores were also higher at 3 months (85 ± 14 versus 68 ± 20, mean difference 17 [95% CI 9 to 24]; p < 0.001) but not at 1 year. Patients with lesser trochanter displacement of < 10 mm also demonstrated better performance in the TUG test at both 3 months (48 ± 31 versus 68 ± 31 seconds, mean difference -20 [95% CI -34 to -5]; p = 0.01) and 1 year (37 ± 27 versus 52 ± 32 seconds, mean difference -15 [-29 to -1]; p = 0.03). No meaningful differences were observed in the FRT or the 5TSTS test at either time point. A higher percentage of patients with < 10 mm of displacement completed the tests (93% [41 of 44] versus 73% [32 of 44]; p < 0.001). Conclusion: Intertrochanteric fractures with ≥ 10 mm of lesser trochanter displacement were associated with some poorer short-term functional and patient performance outcomes compared with patients with less displacement, although these differences diminished over time. The possible clinical benefit of surgically addressing the displaced fragment should be carefully weighed against the risks associated with a more extensive procedure. Further studies are warranted to address this issue. Level of Evidence: Level III, therapeutic study.

31 October 2019 in Obesity Medicine
Verified
Journal Article
Closed access
POPhatcharapa Osateerakun
Phatcharapa Osateerakun
SWSoarawit Weerasopone
Soarawit Weerasopone
CAChavarin Amarase
Chavarin Amarase
SHSittisak Honsawek
Sittisak Honsawek
NLNoppachart Limpaphayom
Noppachart Limpaphayom


6 December 2024 in Medicine
Verified
Journal Article
Open access
NJNonn Jaruthien
Nonn Jaruthien
ATAree Tanavalee
Aree Tanavalee
SNSrihatach Ngarmukos
Srihatach Ngarmukos
CTChotetawan Tanavalee
Chotetawan Tanavalee
CAChavarin Amarase
Chavarin Amarase
PSPakpoom Somrak
Pakpoom Somrak
Background: Several studies have proved that diacerein effectively treats knee osteoarthritis (OA). All studies used branded diacerein. Recently, generic diacerein has been available in several countries, with limited studies comparing the efficacy of generic and branded diacerein for knee OA treatment. Methods: Among 200 eligible patients, 94 were randomized to take a daily 50 mg of generic diacerein (Diaceric®); group A or branded diacerein (Artrodar®); group B for treating mild to moderate knee OA. All patients were assigned 5-visit assessments and followed until 24 weeks. The primary outcome was a visual analog scale (VAS) on the motion. The secondary outcomes were 2 patient-report outcome measures (PROMs): the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and the Short Form-12 (SF-12), as well as 3 performance-based measures (PBMs): 5-time sit to stand test (5 × SST), the time up and go test (TUGT), and the 3-minute walk test (3MWT). Results: There were 47 patients in group A and 47 in group B, with no patients lost for FU. Among all patients, 79.8% were female with a mean age of 63.2 years in group A and 64.8 years in group B. The Kellgren and Lawrence (KL) grade II was the most common in both groups. There were no differences in all demographic data. At 24-week follow-up (FU), both groups had significantly improved VAS, with a 12-week earlier improvement in the branded diacerein. In addition, the PBMs, including 5 × SST and 3MWT, significantly improved from 12-week FU in both groups, with insignificantly improved WOMAC and SF-12 and no serious adverse events in either group. Conclusion: After a 24-week FU, the generic diacerein had similar efficacy as the branded diacerein in significantly improving VAS and PBMs: 5 × SST and 3MWT. However, the latter had a faster statistically improved VAS than the former.

10 November 2025 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
NRNapol Ratanasermsub
Napol Ratanasermsub
CAChavarin Amarase
Chavarin Amarase
STSaran Tantavisut
Saran Tantavisut
PSPathit Sirichuchnin
Pathit Sirichuchnin

15 June 2026 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
NRNapol Ratanasermsub
Napol Ratanasermsub
CAChavarin Amarase
Chavarin Amarase
STSaran Tantavisut
Saran Tantavisut
PSPathit Sirichuchnin
Pathit Sirichuchnin